Hostname: page-component-78c5997874-s2hrs Total loading time: 0 Render date: 2024-11-05T06:04:58.831Z Has data issue: false hasContentIssue false
  • English
  • Français

MPTP-Induced Parkinsonism in the Monkey: Neurochemical Pathology, Complications of Treatment and Pathophysiological Mechanisms

Published online by Cambridge University Press:  05 January 2016

A.R. Crossman ,
C.E. Clarke ,
S. Boyce ,
R.G. Robertson  and
M.A. Sambrook
A.R. Crossman*
Affiliation:
Department of Cell & Structural Biology, School of Biological Sciences, Stopford Building, University of Manchester, Manchester
C.E. Clarke
Affiliation:
Department of Cell & Structural Biology, School of Biological Sciences, Stopford Building, University of Manchester, Manchester
S. Boyce
Affiliation:
Department of Cell & Structural Biology, School of Biological Sciences, Stopford Building, University of Manchester, Manchester
R.G. Robertson
Affiliation:
Department of Cell & Structural Biology, School of Biological Sciences, Stopford Building, University of Manchester, Manchester
M.A. Sambrook
Affiliation:
Department of Cell & Structural Biology, School of Biological Sciences, Stopford Building, University of Manchester, Manchester
*
Department of Cell & Structural Biology, School of Biological Sciences, Stopford Building, University of Manchester, Manchester, U.K. M13 9PT
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

MPTP induces parkinsonism in monkeys by destruction of the substantia nigra, pars compacta. It can also damage ventral tegmental dopamine neurones and the noradrenergic locus coeruleus, both of which may be affected in Parkinson's disease. Motor symptoms in MPTP-treated monkeys respond readily to levodopa or dopamine agonist therapy. Administration of levodopa over 4-8 weeks leads to the emergence of “peak- dose” dyskinesia. Such abnormal movements are not seen following challenge doses of levodopa in animals not on long-term therapy. Radioligand studies reveal a 40-180% increase in D2 receptor binding in the striatum of parkinsonian monkeys. 2-deoxyglucose studies of regional brain metabolism indicate that MPTP-induced parkinsonism is characterised by abnormally increased activity of medial pallidal neurones which project to the thalamus and pedunculopontine nucleus and reduced activity of subthalamic nucleus neurones.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 14 , Issue S3 , August 1987 , pp. 428 - 435
Copyright
Copyright © Canadian Neurological Sciences Federation 1987

References

REFERENCES

1.Davis, GC, Williams, AC, Markey, SP, et al. Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiat Res 1979; 1: 249–254.CrossRefGoogle ScholarPubMed
2.Langston, JW, Ballard, P, Tetrud, JW, et al. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 219: 979–980.CrossRefGoogle ScholarPubMed
3.Langston, JW.MPTP and Parkinson’s disease. Trends in Neuro sci 1985; 8: 79–83.CrossRefGoogle Scholar
4.Langston, JW, Ballard, P.Parkinsonism induced by l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP): Implications for treatment and the pathogenesis of Parkinson’s disease. Can J Neurol Sci 1984; 11: 160–165.CrossRefGoogle Scholar
5.Burns, RS, Chiueh, CC, Markey, SP, et al. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci U.S.A. 1983; 80: 4546–4550.CrossRefGoogle ScholarPubMed
6.Burns, RS, Markey, SP, Phillips, JM, et al. The neurotoxicity of 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the monkey and man. Can J Neurol Sci 1984; 11: 166–168.CrossRefGoogle ScholarPubMed
7.Chiueh, CC, Markey, SP, Burns, RS, et al. Selective neurotoxic effects of N-methyl-4-phenyl-l ,2,3,6-tetrahydropyridine (MPTP) in subhuman primates and man: a new animal model of Parkinson’s disease. Psychopharmacol Bull 1984; 20: 548–553.Google Scholar
8.Mettler, FA.Effects of bilateral simultaneous subcortical lesions in the primate. J Neuropath Exp Neurol 1945; 4: 99–122.CrossRefGoogle Scholar
9.Denny-Brown, D.The Basal Ganglia and Their Relation to Disorders of Movement, Oxford Neurological Monographs (Russell, WR, ed.), Oxford University Press, London, 1962.Google Scholar
10.Richter, R.Degeneration of the basal ganglia in monkeys from chronic carbon disulphide poisoning. J Neuropath Exp Neurol 1945; 4: 324–353.CrossRefGoogle Scholar
11.Langston, JW, Forno, LS, Rebert, CS, et al. Selective nigral toxicity after systemic administration of 1 -methyl-4-pheny I-1,2,5,6-tetrahydropyridine (MPTP) in the squirrel monkey. Brain Res 1984; 292: 390–394.CrossRefGoogle Scholar
12.Crossman, AR, Mitchell, IJ, Sambrook, MA.Regional brain uptake of2-deoxyglucoseinN-methyl-4-phenyl-l,2,3,6-tetrahydropyri-dine (MPTP)-induced parkinsonism in the macaque monkey. Neuropharmacology 1985; 24: 587–591.CrossRefGoogle ScholarPubMed
13.Mitchell, IJ, Cross, AJ, Sambrook, MA, Crossman, AR.Sites of the neurotoxic action of 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the monkey include the ventral tegmental area and the locus coeruleus. Neurosci Letts 1985; 61: 195–200.CrossRefGoogle ScholarPubMed
14.Jenner, P, Rupniak, NMJ, Rose, S, et al. l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset. Neurosci Letts 1984; 50: 85–90.CrossRefGoogle Scholar
15.Clarke, CE, Sambrook, MA, Mitchell, IJ, Crossman, AR.Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with l-methyl-4-phenyl-l ,2,3,6-tetrahydropyridine (MPTP). J Neurol Sci 1987; 78: 273–280.CrossRefGoogle Scholar
16.Chiueh, CC, Burns, RS, Markey, SP, et al. Primate model of parkinsonism: selective lesion of nigrostriatal neurons by l-methyl-4-phenyl-l ,2,3,6-tetrahydropyridine produces an extrapyramidal syndrome in rhesus monkeys. Life Sci 1985; 36: 213–218.CrossRefGoogle Scholar
17.Forno, LS, Langston, JW, Delanney, LE, et al. Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. Ann Neurol 1986; 20: 449–455.CrossRefGoogle ScholarPubMed
18.Marsden, CD, Parkes, JD, Quinn, N.Fluctuations of disability in Parkinson’s disease - clinical aspects. In: Movement Disorders (Marsden, CD & Fahn, S, eds.), Butterworths, London, 1982: 96–122.Google Scholar
19.Lesser, RP, Fahn, S, Snider, S, et al. Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology 1979; 29: 1253–1260.CrossRefGoogle ScholarPubMed
20.Rajput, AH, Stern, W, Laverty, WH.Chronic low-dose levodopa therapy in Parkinson’s disease: an argument for delaying levodopa therapy. Neurology 1984; 34: 991–996.CrossRefGoogle ScholarPubMed
21.Hoehn, MM, Yahr, MD.Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427–442.CrossRefGoogle ScholarPubMed
22.Crossman, AR, Sambrook, MA, Jackson, A.Experimental hemiballismus in the baboon produced by injection of a gamma-aminobutyric acid antagonist into the basal ganglia. Neurosci Letts 1980; 20: 369–372.CrossRefGoogle ScholarPubMed
23.Crossman, AR, Sambrook, MA, Jackson, A.Experimental hemichorea/hemiballismus in the monkey. Studies on the intracerebral site of action in a drug-induced dyskinesia. Brain 1984; 107: 579–596.CrossRefGoogle Scholar
24.Guttman, M, Seeman, P.L-dopa reverses the elevated density of dopamine D2 receptors in Parkinson’s diseased striatum. J Neural Transm 1985; 64: 93–103.CrossRefGoogle ScholarPubMed
25.Bedard, P, Di Paolo, T, Falardeau, P, et al. Chronic treatment with L-dopa, but not bromocriptine induces dyskinesia in MPTP-treated parkinsonian monkeys. Correlation with [3H] spiperone binding. Brain Res 1986; 379: 294–299.CrossRefGoogle ScholarPubMed
26.Joyce, JN, Marshall, JF, Bankiewicz, KS, et al. Hemiparkinsonism in a monkey after unilateral internal carotid artery infusion of 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is associated with regional ipsilateral changes in striatal dopamine D-2 receptor density. Brain Res 1986; 382: 360–364.CrossRefGoogle Scholar
27.Sokoloff, L, Reivich, M, Kennedy, C, et al. M. The [14C] deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 1977; 28: 897–916.CrossRefGoogle Scholar
28.Mata, M, Fink, DJ, Gainer, H, et al. Activity-dependent energy metabolism in rat posterior pituitary primarily reflects sodium pump activity. J Neurochem 1980; 34: 213–215.CrossRefGoogle ScholarPubMed
29.Schwartz, WJ, Smith, CB, Davidsen, L, et al. Metabolic mapping of functional activity in the hypothalamo-neurohypophysial system of the rat. Science 1979; 205: 723–725.CrossRefGoogle ScholarPubMed
30.Mitchell, IJ, Cross, AJ, Sambrook, MA, Crossman, AR.Neural mechanisms mediating l-methyl-4-phenyl-l ,2,3,6-tetrahydropyridine-induced parkinsonism in the monkey: relative contributions of the striatopallidal and striatonigral pathways as suggested by 2-deoxyglucose uptake. Neurosci Letts 1986; 63: 61–65.CrossRefGoogle Scholar
31.Crossman, AR.Primate models of dyskinesia: The experimental approach to the study of basal ganglia-related involuntary movement disorders. Neuroscience 1987; 21: 1–40.CrossRefGoogle Scholar
32.Mitchell, IJ, Jackson, A, Sambrook, MA, Crossman, AR.Common neural mechanisms in experimental chorea and hemiballismus in the monkey. Evidence from 2-deoxyglucose autoradiography. Brain Res 1985; 339: 346–350.CrossRefGoogle ScholarPubMed
33.Mitchell, IJ, Sambrook, MA, Crossman, AR.Subcortical changes in the regional uptake of [3H]-2-deoxyglucose in the brain of the monkey during experimental choreiform dyskinesia elicited by injection of a gamma-aminobutyric acid antagonist into the subthalamic nucleus. Brain 1985; 108: 421–438.CrossRefGoogle ScholarPubMed